These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25062765)

  • 1. Rhes suppression enhances disease phenotypes in Huntington's disease mice.
    Lee JH; Sowada MJ; Boudreau RL; Aerts AM; Thedens DR; Nopoulos P; Davidson BL
    J Huntingtons Dis; 2014; 3(1):65-71. PubMed ID: 25062765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes.
    Harrison LM; Lahoste GJ
    Exp Cell Res; 2013 Sep; 319(15):2310-5. PubMed ID: 23583659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
    Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
    Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.
    Lee JH; Tecedor L; Chen YH; Monteys AM; Sowada MJ; Thompson LM; Davidson BL
    Neuron; 2015 Jan; 85(2):303-15. PubMed ID: 25556834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal Induction and Spread of the Huntington's Disease Protein: A Novel Rhes Route.
    Subramaniam S
    J Huntingtons Dis; 2022; 11(3):281-290. PubMed ID: 35871361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).
    Subramaniam S; Snyder SH
    Neuropharmacology; 2011 Jun; 60(7-8):1187-92. PubMed ID: 21044641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity.
    Subramaniam S; Sixt KM; Barrow R; Snyder SH
    Science; 2009 Jun; 324(5932):1327-30. PubMed ID: 19498170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease.
    Baiamonte BA; Lee FA; Brewer ST; Spano D; LaHoste GJ
    PLoS One; 2013; 8(1):e53606. PubMed ID: 23349722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
    Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Rhes knockout in the Q175 Huntington's disease mouse model.
    Heikkinen T; Bragge T; Kuosmanen J; Parkkari T; Gustafsson S; Kwan M; Beltran J; Ghavami A; Subramaniam S; Shahani N; Ramírez-Jarquín UN; Park L; Muñoz-Sanjuán I; Marchionini DM
    PLoS One; 2021; 16(10):e0258486. PubMed ID: 34648564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.
    Marco S; Giralt A; Petrovic MM; Pouladi MA; Martínez-Turrillas R; Martínez-Hernández J; Kaltenbach LS; Torres-Peraza J; Graham RK; Watanabe M; Luján R; Nakanishi N; Lipton SA; Lo DC; Hayden MR; Alberch J; Wesseling JF; Pérez-Otaño I
    Nat Med; 2013 Aug; 19(8):1030-8. PubMed ID: 23852340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
    DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
    Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.
    Mealer RG; Subramaniam S; Snyder SH
    J Neurosci; 2013 Feb; 33(9):4206-10. PubMed ID: 23447628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease.
    Sbodio JI; Paul BD; Machamer CE; Snyder SH
    Cell Rep; 2013 Sep; 4(5):890-7. PubMed ID: 24012756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.